Effectiveness of carnosine on disturbed electrolytes homeostasis induced by cisplatin by Noori, S & Mahboob, T
African Journal of Biotechnology Vol. 10(37), pp. 7286-7293, 20 July, 2011     
Available online at http://www.academicjournals.org/AJB 
DOI: 10.5897/AJB11.202 
ISSN 1684–5315 © 2011 Academic Journals  
 
 
 
 
Full Length Research Paper 
 
Effectiveness of carnosine on disturbed electrolytes 
homeostasis induced by cisplatin 
 
Shafaq Noori* and Tabassum Mahboob 
 
Department of Biochemistry, Clinical Biophysics Research Unit, University of Karachi 75270, Pakistan 
 
Accepted 1 June, 2011 
 
We aimed to assess the effect of well known antioxidant carnosine on disturbed plasma and intra-
erythrocytes electrolytes and Na
+
-K
+
-ATPase activity by cisplatin.  24 male albino Wistar rats were 
selected and divided into 4 groups: Group I = untreated control; Group II = cisplatin control (received 
cisplatin at a dose of 3 mg/ kg body weight; i.p. for 13 alternate days); Group III = carnosine alone 
(treated group at a dose of 10 mg/kg body weight; i.p. for 13 consecutive days); Group IV = carnosine + 
cisplatin pretreated group. Carnosine was administered 30 min prior to cisplatin. Carnosine 
significantly restored the intra – erythrocytes Na
+
, K
+
 and Na
+
-K
+
-ATPase level which consequently 
affect the plasma Na
+
, Ca
++
, and Mg
++
 level. Effective role conferred by carnosine exhibits its protective 
activity. 
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INTRODUCTION 
 
Cisplatin and other platinum derivatives are among the 
most effective antineoplastic drugs used for the treatment 
of solid tumors. Cisplatin DNA cross links, cause 
cytotoxic lesions in tumors, and other dividing cells. DNA 
damaging agents usually have less toxicity in non - 
proliferating cell, yet the quiescent proximal tubule cells 
are selectively damaged by cisplatin (Schrier et al., 
2004). A potential mechanism influencing the sensitivity 
of the cells to cisplatin may result from the interaction of 
specific proteins with cisplatin–damaged DNA (Arany and 
Safirstein, 2003; Kuriakose and Kurup, 2008). RNA and 
protein also interact with cisplatin. Cisplatin protein 
interactions are the determining step for the therapeutic 
efficacy of antitumor agents. These interactions alter the 
rate of clearance of the drug from circulations, thus, are 
responsible for toxicity to the kidneys and gastrointestinal 
tract dysmotility (Cabezos et al., 2010). Moreover, 
cisplatin changed the liver enzymes activities (Ray et al., 
2006). Decreased body weight, haemoglobin levels and 
leucocyte counts were observed with cisplatin adminis-
tration (Bogin et al., 1994). Electrolytes disturbances are 
also associated with cisplatin therapy (Blachley  and  Hill, 
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1981). 
Carnosine is a naturally occurring histidine containing 
dipeptide also known as β – alanyl – L- histidine (Hipkiss 
et al., 1998), has number of roles such as buffering, 
quenching free radicals, enzyme regulation and sarco-
plasmic reticulum calcium regulation (Gulshanara et al., 
2005; Suer et al., 2011). 
Carnosine regulated calcium has been previously 
reported. This study was conducted to evaluate the 
possible role of carnosine, if any, on depressed Na
+
 K
+
 
ATPase activity related to ion homeostasis induced by 
cisplatin. 
 
 
MATERIALS AND METHODS 
 
Animals and diet 
 
24 Wistar albino rats, of male sex (200 to 260 g body weight), 
purchased from the animal house of ICCBS (International center for 
Chemical and Biological Center Karachi, Pakistan), were used for 
the study. Animals were acclimatized to the laboratory conditions 
one week before the start of experiment and caged in a quite 
temperature controlled room (23±4°C). Rats had free access to 
water and standard rat diet. The experiments were conducted in 
accordance with ethical guidelines of internationally accepted 
principles for Laboratory use and care in animal research (Health 
research extension Act of 1985). 
 
 
 
 
Study design 
 
The animals were randomly divided into four experimental groups 
(n = 6). Each group consists of six rats and received the following 
treatment: 
 
Group I: Control group remains untreated 
Group II: (positive cisplatin control) received cisplatin i.p. (3 mg/kg 
body weight) for 5 alternate days 
Group III: Received carnosine i.p. (10 mg/kg body weight) for 10 
consecutive days  
Group IV: Received cisplatin i.p. (3 mg/kg body weight) for 5 
alternate days + Carnosine i.p. (10 mg/kg body weight) 30 min prior 
to cisplatin, for 10 consecutive days 
 
 
Sample collection 
 
After 48 h of last dose of treated groups, animals were decapitated 
and blood was sampled from head wound in the lithium heparin 
coated tubes. The collected blood was mixed gently. A portion of 
blood was used to collect plasma. The blood was then transferred 
to the clean glass tube and centrifuged at 2000 rpm for 20 min. The 
plasma was separated and collected in disposable Eppendorff 
tubes and stored at -70°C till analysis.  
 
 
Analytical method 
 
Assessment of electrolytes homeostasis 
 
Plasma separation for electrolytes estimation: Plasma was 
separated from heparinized blood by centrifugation and analyzed 
for the estimation of sodium and potassium by flame photometry 
(Corning 410), and estimation of plasma calcium ion by ion 
selective electrode method jenway (Ion Meter 3345) 
 
Estimation of intra - erythrocyte sodium and potassium: 
Washed erythrocytes used for the estimation of intra - erythrocytes 
sodium and potassium were mixed with gentle inversion and a 
microhaematocrit capillary sample for packed cell volume 
determination was taken. Suspension of cells was then lyzed by 
adding 0.01 ml of saponin solution (20% in MgCl2 112 mM). 0.3 ml 
of well mixed lysate was added to 10 ml of lithium nitrate diluent (15 
mM) with an automatic pipette. Concentration of erythrocyte sodium 
and potassium was calculated as mM. 
 
Estimation of plasma sodium and potassium: Plasma was 
diluted 1:100 with 0.1 NHCl and was used for simultaneous 
determination of sodium and potassium. The emission intensities of 
standards and sample were recorded against the respective blank 
solutions. The emission intensities of sodium, potassium were 
recorded at 589 and 768 nm respectively.  
 
Erythrocyte membrane preparation: Heparinized blood was 
centrifuged and plasma was separated. Buffy coat was aspirated 
and discarded. Erythrocytes were washed three times at room 
temperature by suspension in the magnesium chloride solution (112 
mM), centrifugation at 450 × g at 4°C for 5 min. Final supernatant 
was retained for the estimation of intra erythrocyte sodium and 
potassium concentration. Neither electrolyte was detectable in the 
final wash. The packed red cells extracted  by centrifugation at 4°C, 
450 × g for 15 min were resuspended and diluted in 25 volumes of 
0.011 M Tris-HCl buffer at pH = 7.4. The hemolyzed cells were then 
centrifuged for 30 min at 12,000 rpm at 4°C and the membrane 
pellet was resuspended in 30 ml of 0.011 M Tris-HCl buffer. This 
centrifugation step was repeated three times. The final 
concentration of the membrane  suspension  was ~4 mg  protein/ml  
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of Tris buffer. The concentration of protein was estimated by Biuret 
Method (Savory et al., 1968). The membrane suspension was 
stored at -80°C until the assay was performed.  
 
Erythrocyte Na
+
-K
+
-ATPase activity measurement (Denis et al., 
1996): ATPase activity was measured in a final volume of 1 ml as 
follows: membrane (400 µg) were pre-incubated for 10 min at 37°C 
in a mixture containing 92 mM Tris-HCl (pH = 7.4), 100 mM NaCl, 
20 mM KCl, 5 mM MgSO4.H2O and 1 mM EDTA. Assays were 
performed with or without 1 mM ouabain, a specific inhibitor of Na-
K-ATPase activity was calculated as the difference between 
inorganic phosphates released during the 10 min incubation with 
and without ouabain. Activity was corrected to a nanomolar 
concentration of inorganic phosphate released mg protein/hour.
 
All assays were performed in duplicate, and blanks for substrate, 
membrane and incubation time were included to compensate for 
endogenous phosphate and non - enzyme related breakdown of 
ATP. Under these experimental conditions, the coefficient of 
variation was 7.5%. 
 
Estimation of plasma magnesium (Hallry and Sky Peck, 1964): 
Concentration of magnesium in plasma was estimated by the 
method described earlier by Hallry and Sky Peck (1964). A protein 
free filtrate was prepared by mixing 0.2 ml of plasma with 1.8 ml 
TCA (5% w / v). Standard magnesium solution (5 mg %) was also 
treated in the same manner. 1 ml of filtrate was taken in separate 
tubes. 1.5 ml of titan yellow (0.05%) and 0.5 ml of NaOH (4 N) was 
added. A blank was prepared by taking 1 ml of deionized water and 
treated similarly as test and standards. The color intensity was 
measured against blank at 540 nm after 15 min on Schimdzu-
spectrophotometer UV-120-01. 
 
 
Statistical analysis 
 
Results were presented as mean ± SD. Statistical significance and 
difference from control and test values were evaluated by Student’s 
t-test. P-values of P < 0.001, P < 0.01 and P < 0.05 were 
considered significant. 
Significant difference between control with cisplatin, carnosine 
and cisplatin + carnosine - pretreated rats by t-test were **P < 0.05, 
*P < 0.01, ***P<0.001 respectively. Significant difference between 
positive control, cisplatin with carnosine and cisplatin + carnosine - 
pretreated rats by t-test were +++P<0.001, ++P < 0.05, +P < 0.01 
respectively. 
 
 
 RESULTS 
 
 Intra - erythrocyte sodium level in control, CDDP, 
carnosine and CDDP + carnosine - pretreated rats  
 
Intra - erythrocyte sodium level was increased (P < 0.01) 
in cisplatin treated rats (Figure 1). In cisplatin + carnosine 
group, the increased sodium level was prevented (P < 
0.001) while carnosine alone showed decreased sodium 
level (P<0.01) as compared with the positive control. 
 
 
Intra - erythrocyte potassium level in control, CDDP, 
carnosine and CDDP + carnosine - pretreated rats 
 
Figure 2 shows a marked decreased erythrocyte 
potassium level (P < 0.05) in cisplatin treated rats as 
compared with the control  group  while  carnosine  alone  
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Figure 1. Intra - erythrocytes Na 
+
 level in control, Cisplatin, Carnosine and 
Cisplatin + Carnosine - pretreated rats. *P < 0.01, **P < 0.05 compared with 
control, +P<0.01,+++P<0.001 compared with cisplatin. 
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Figure 2. Intra-erythrocytes K
+
 level in control, cisplatin, carnosine and cisplatin + 
carnosine - pretreated rats. **P < 0.05 compared with control,++P<0.05 
compared with cisplatin. 
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Figure 3. Intra - erythrocytes Na
+
-K
+
-ATPase level in control, cisplatin, carnosine 
and cisplatin + carnosine - pretreated rats. *P<0.01 compared with control, 
++P<0.05 compared with cisplatin. 
 
 
 
treatment showed no significant results. Pretreatment of 
carnosine partially prevented the decreased levels of 
potassium (P<0.05) as compared to positive control. 
 
 
Intra - erythrocyte Na
+
-K
+
-ATPase level in control, 
CDDP, carnosine and CDDP + carnosine - pretreated 
rats 
 
Cisplatin treated group showed a marked decreased in 
Na
+
-K
+
-ATPase level (P < 0.01) as compared with the 
control (Figure 3). CDDP + carnosine treated rats pre-
vented  decrease Na
+
-K
+
-ATPase level (P<0.05 ), while 
alone carnosine showed no significant results as com-
pared to positive control. 
 
 
Plasma magnesium level in control, CDDP, carnosine 
and CDDP + carnosine - pretreated rats 
 
Figure 4 shows that a significant decreased plasma 
magnesium level (P < 0.01) was observed in cisplatin 
treated rats as compared with the control. The decreased 
magnesium level was partially prevented in carnosine + 
CDDP group (P < 0.01). Alone carnosine treatment 
showed significant increased level (P < 0.01) as 
compared to positive control. 
 
 
Plasma calcium level in control, cisplatin treated, 
carnosine treated and cisplatin + carnosine - 
pretreated rats 
 
Figure 5 shows a significant effect on plasma calcium 
level in cisplatin – treated rats. Calcium level was signifi-
cantly decreased (P < 0.01) in cisplatin treated rats as 
compared with the control. Pretreatment with carnosine 
partially prevented increase in plasma calcium level in 
CDDP + carnosine (P < 0.05) group and alone carnosine 
group showed slight increased calcium level (P < 0.05) as 
compared with the positive control. 
 
 
Plasma sodium level in control, CDDP, carnosine and 
CDDP + carnosine - pretreated rats 
 
Figure 6 shows the significant effect on plasma sodium 
level in cisplatin treated rats. Sodium level was decrea-
sed in cisplatin treated (P < 0.05) rats as compared to   
the control group. Pretreatment with carnosine  prevented  
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Figure 4. Plasma Mg
++
 level in control, cisplatin, carnosine and cisplatin + 
carnosine - pretreated rats. *P<0.01, ***P<0.001 compared with control,+P<0.01 
compared with cisplatin 
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Figure 5. Plasma Ca
++
 level in control, cisplatin, carnosine and cisplatin + 
carnosine - pretreated rats. *P<0.01,***P<0.001 compared with 
control,+P<0.01,++P<0.05 compared with Cisplatin 
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Figure 6. Plasma Na 
+
 level in control, cisplatin, carnosine and cisplatin + carnosine - 
pretreated rats. **P < 0.05, *P<0.01 compared with control, +++P<0.001 compared 
with cisplatin. 
 
 
 
the decrease in serum sodium level (P<0.001). Alone 
carnosine treatment showed increased sodium level (P < 
0.001). 
 
 
Plasma potassium level in control, CDDP, carnosine 
and CDDP + carnosine - pretreated rats 
 
Figure 7 shows non-significant increased potassium level 
in cisplatin treated rats as compared to the control. The 
results were not different in CDDP + carnosine group as 
compared to the control. While alone carnosine treatment 
showed no significant results. 
 
 
DISCUSSION 
 
In this study, we investigated the effect of cisplatin on 
plasma and membrane electrolytes because of their 
importance in the homeostasis of cell and its protection 
by carnosine. Our results demonstrated that plasma 
calcium, magnesium and sodium (Figures 4, 5 and 6), 
intra - erythrocytes potassium and enzyme Na
+
-K
+
-
ATPase (Figures 2  and  3)  significantly  decreased  after 
cisplatin administration (3 mg/kg body weight). Similarly, 
intra-erythrocytes sodium, and plasma potassium 
(Figures 1 and 7) levels significantly increased. 
Previously, it has been reported that hypocalcaemia is a 
known side-effect in high-dose cisplatin chemotherapy of 
solid tumors (Arany and Safirstein, 2003). Hypocalcaemia 
is caused by excessive urinary loss and decreased renal 
up-take during high-dose cisplatin treatment. Proximal 
tubular damage leads to decreased reabsorption of 
cations. Calcium plays a key role in regulating cell meta-
bolic processes by stimulating or inhibiting key enzymes 
(Zhang and Lindup, 1996). Cisplatin stimulate stage 4 
respiration, which is similar to uncoupling of oxidative 
phosphorylation (Binet and Volfin, 1977), causing efflux 
Ca
+2
 from the mitochondria. Cells must keep the 
intracellular Ca
++
 concentration at a very low level to 
maintain Na
+
-K
+
-ATPase in an active state (Zhang and 
Lindup, 1996). Guarino et al. (1979) reported that 
increased levels of intracellular Ca
+2
 are known to shut 
down Na
+
-K
+
-ATPase, which is an integral glycoprotein of 
the plasma membrane.  
It is found that the loss of ATP leads to disruption of 
cellular ion homeostasis with decreased cellular K
+ 
content,     increased     Na
+
    content    and    membrane  
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Figure 7. Plasma K
+
 level in Control, Cisplatin, Carnosine and Cisplatin + Carnosine - 
pretreated rats. 
 
 
 
depolarization. Increased cytosolic free Ca
2+
 concen-
trations can occur in the early or late phase of cell injury 
and play a critical role leading to cell death (Goren, 
2003). The Na
+
-K
+
-pump at the cellular membrane main-
tains a high cellular potassium concentration by active 
transport against a considerable gradient. Magnesium 
acts as a substrate for Na
+
-K
+
-ATPase, thus, hypomag-
nesium impaired the pump activity (Lajer et al., 2005).  
Cell permeability and potassium gradient increased, so 
potassium leaves the cell and in compensation an influx 
of sodium and hydrogen ions will take place passively. 
Also, magnesium leaves the cell, if not enough ATP is 
present for forming the ATP - Mg complex and calcium 
influx will follow (Lajer et al., 2003). Carnosine at a dose 
of 10 mg/ kg partially restored the calcium, magnesium 
and Na
+
-K
+
-ATPase level (Figures 3, 4 and 5) which 
implicates the Na+ and K
+
 level as shown in Figures 1and 
2. 
Previously, was reported that cisplatin the increased 
ROS (reactive oxygen species) (Shafaq and Tabassum, 
2010) which consequently altered the mem-brane 
permeability, thus, disturbed the electrolytes home-
ostasis as described earlier. ROS has high affinity 
towards the thiol group, which oxidized – SH (thiol) group 
of Na
+
-K
+
-ATPase and decreased its activity. It is found 
from present results that carnosine treatment regulated 
the altered electrolytes homeostasis and activated Na
+
-
K
+
-ATPase by scavenging the reactive oxygen species 
which subsequently restored the membrane permeability. 
Finally, electrolytes homeostasis of carnosine is also a 
Ca
++
 regulator, known previously to maintain Na
+
-K
+
-
ATPase activity. 
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